AINOSTICS develops AI algorithms and MRI measurement techniques to identify early biological signs of neurological disorders, such as Alzheimer's disease and multiple sclerosis. Their platform enhances clinical diagnosis and treatment planning by providing automated, data-driven insights from multi-modal imaging and non-imaging data.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological disorders like Alzheimer's disease and multiple sclerosis are difficult to diagnose early, delaying treatment and impacting patient outcomes. Traditional diagnostic methods often lack the sensitivity to detect subtle changes in brain tissue that precede noticeable symptoms. This necessitates more advanced tools for early and accurate detection.
Solution
AINOSTICS develops AI-powered algorithms and MRI measurement techniques to identify early biological signs of neurological disorders. Their platform analyzes multi-modal imaging and non-imaging data to provide automated, data-driven insights for enhanced clinical diagnosis and treatment planning. By combining medical imaging innovations with artificial intelligence, AINOSTICS aims to unlock personalized diagnosis, prognosis, and therapy monitoring. Their solutions are designed to augment human knowledge with objectivity and reliability, addressing the unmet needs of the clinical environment.
Target Audience
The primary users are clinicians and pharmaceutical companies involved in the diagnosis, treatment, and research of neurological disorders.
Features
- AI-powered analysis of multi-modal clinical imaging and non-imaging data
- Algorithms for improved workflow across the entire clinical imaging pathway
- State-of-the-art image acquisition, quality control, data encoding, modeling, and inference techniques
- BR[AI]N® product with FDA Breakthrough Device designation for predicting conversion to Alzheimer's disease using structural MRI scans